Company: Insulet ($PODD)
Drug delivered: insulin
Why it's important: In the valuable diabetes market, one delivery device making headway is Insulet's next-gen OmniPod, the combination lightweight insulin pump and wireless glucometer. With FDA approval notched earlier this year, the first-of-its-kind tubing-free pump offers continuous glucose monitoring in a sleek design.
Having worked together with DexCom ($DXCM) since 2008, Insulet went its own way just before the FDA approved the OmniPod. But with its new, undisclosed partner, Insulet could make a run at Medtronic ($MDT); the company's Paradigm is the only other integrated insulin pump and glucose monitor currently on the market. Insulet's tubeless version, though, could be the one to watch.
By offering a more seamless alternative to traditional insulin pumps, the newest OmniPod has the potential to make a dent this year in the valuable diabetes market.
Special Report: Top 5 Insulin-Delivery Techs To Watch
FDA approves Insulet's next-gen OmniPod insulin device
Insulet ditches DexCom in diabetes collaboration